Montelukast Sodium Market Size to Hit USD 1.88 Billion by 2035

The global montelukast sodium market is expanding steadily due to the rising prevalence of asthma, allergic rhinitis, and other chronic respiratory conditions. In 2025, the market size was valued at USD 1.07 billion and is projected to increase to USD 1.13 billion in 2026. By 2035, the market is expected to reach approximately USD 1.88 billion, growing at a CAGR of 5.80% from 2026 to 2035.

The increasing burden of respiratory diseases, greater awareness about preventive therapies, and growing access to healthcare services are among the key factors driving demand for montelukast sodium globally.

Read Also: Thrombus Aspiration Catheter Market

Market Overview

Montelukast sodium is a leukotriene receptor antagonist commonly used in the treatment of asthma, allergic rhinitis, exercise-induced bronchospasm, chronic urticaria, and other respiratory conditions. It works by blocking leukotrienes, inflammatory chemicals that cause airway constriction, swelling, and mucus production.

The drug is widely prescribed as a long-term maintenance therapy because of its ability to reduce asthma symptoms, prevent allergy flare-ups, and improve patient quality of life. The increasing use of montelukast sodium in combination therapies and the availability of multiple dosage forms are further supporting market growth.

Key Takeaways

• Market size in 2025: USD 1.07 billion
• Market size in 2026: USD 1.13 billion
• Projected market size by 2035: USD 1.88 billion
• CAGR from 2026 to 2035: 5.80%
• North America dominated the market with a 35% share in 2025
• Asia Pacific is expected to grow at the fastest CAGR of 6.8%
• Tablets held the largest dosage form share at 70% in 2025
• Asthma accounted for the largest application share at 50%
• Hospital pharmacies dominated the distribution channel segment with a 40% share in 2025

Market Drivers

Increasing Prevalence of Respiratory Diseases

One of the primary growth drivers for the montelukast sodium market is the increasing prevalence of asthma, allergic rhinitis, and exercise-induced bronchospasm. Rapid urbanization, air pollution, smoking, climate change, and genetic predisposition are contributing to the rising number of respiratory disease cases worldwide.

Healthcare providers are increasingly recommending montelukast sodium as part of long-term treatment plans due to its effectiveness in reducing symptoms and preventing flare-ups.

Growing Geriatric Population

The aging global population is significantly contributing to market growth because elderly individuals are more likely to develop chronic respiratory diseases and allergic conditions. As healthcare providers focus on preventive and long-term disease management, the use of montelukast sodium is increasing among older adults.

Rising Demand for Combination Therapies

Research and development efforts are driving the development of improved formulations and combination therapies involving montelukast sodium. These new therapies offer better treatment outcomes, especially for patients with severe asthma or multiple respiratory conditions.

Market Restraints

Despite positive growth prospects, the montelukast sodium market faces certain challenges. Concerns regarding potential side effects, such as mood changes and neuropsychiatric reactions, may impact patient adoption in some regions. In addition, competition from alternative respiratory drugs, generic medicines, and biologic therapies may limit market expansion.

Strict regulatory approval requirements and pricing pressure in generic drug markets also remain key challenges for manufacturers.

Market Opportunities

The market presents strong opportunities through the growing adoption of online pharmacies, expanding healthcare access in emerging economies, and increasing demand for pediatric formulations. The rising popularity of chewable tablets and oral granules for children and elderly patients is expected to create additional growth avenues.

Moreover, increasing healthcare infrastructure in Asia Pacific, Latin America, and the Middle East is likely to improve access to diagnosis and treatment, thereby boosting montelukast sodium demand.

Segment Analysis

By Dosage Form

The tablets segment dominated the market with a 70% share in 2025 due to its convenience, ease of storage, and standardized dosing. Tablets are the preferred dosage form for treating asthma and allergic rhinitis because they are easy to administer and widely accepted by patients.

The oral granules segment held a 25% share in 2025 and is expected to grow at the fastest CAGR of 6.5% during the forecast period. Oral granules are increasingly popular among pediatric and elderly patients who may have difficulty swallowing tablets. Their ability to provide flexible dosing and improved taste is driving segment growth.

By Application

The asthma segment led the market with a 50% share in 2025 due to the high global prevalence of asthma and the widespread use of montelukast sodium as a maintenance therapy.

The allergic rhinitis segment held the second-largest share and is expected to grow at the fastest CAGR of 6.5% over the forecast period. This growth is being driven by increasing allergy cases caused by pollution, climate change, and seasonal triggers. Chronic urticaria and other applications are also contributing to overall market demand.

By Distribution Channel

Hospital pharmacies dominated the market with a 40% share in 2025 because hospitals are often the first point of diagnosis and treatment for chronic respiratory diseases. Patients with severe asthma or allergies are more likely to receive montelukast prescriptions through hospitals.

Retail pharmacies held the second-largest share, supported by widespread access to prescription medications and consumer preference for nearby pharmacy services. Online pharmacies are expected to grow at the fastest CAGR of 8% because they offer convenience, competitive pricing, and home delivery services.

Regional Insights

North America

North America dominated the global montelukast sodium market with a 35% share in 2025. The region benefits from a high prevalence of asthma, advanced healthcare infrastructure, strong awareness about respiratory diseases, and easy access to medications.

The United States is the largest contributor to regional growth due to its robust pharmaceutical industry, widespread healthcare coverage, and growing demand for both branded and generic montelukast products.

Asia Pacific

Asia Pacific is expected to grow at the fastest CAGR of 6.8% during the forecast period. This growth is driven by increasing pollution levels, rising healthcare spending, improving healthcare infrastructure, and a growing burden of asthma and allergies in countries such as China and India.

The expansion of pharmaceutical manufacturing and increasing access to online pharmacies are also supporting market growth across the region.

Europe

Europe remains a significant market for montelukast sodium due to high healthcare awareness, strong reimbursement systems, and increasing prevalence of respiratory conditions. Government efforts to improve allergy and asthma management programs are also supporting demand in the region.

Market Trends

Increasing Use of Pediatric Formulations

The demand for chewable tablets and oral granules is rising because these formulations are easier for children to consume and offer better taste and dosing flexibility.

Expansion of Online Pharmacies

Consumers are increasingly purchasing respiratory medications through online pharmacies because of home delivery convenience, competitive pricing, and improved access to various formulations.

Focus on Long-Term Maintenance Therapy

Healthcare providers are increasingly prescribing montelukast sodium as a preventive and maintenance therapy instead of relying only on emergency treatment for asthma and allergies.

Competitive Landscape

Key companies operating in the montelukast sodium market are focusing on product innovation, generic drug expansion, and strategic partnerships to strengthen their market position. Manufacturers are investing in improved formulations, pediatric-friendly dosage forms, and wider distribution networks to capture growing demand.

The market is expected to remain highly competitive due to the presence of branded and generic pharmaceutical companies across North America, Europe, and Asia Pacific.

Conclusion

The global montelukast sodium market is expected to grow steadily over the next decade, reaching approximately USD 1.88 billion by 2035. Rising respiratory disease prevalence, growing awareness about long-term asthma management, and improved healthcare access are expected to remain major growth drivers.

North America will likely continue to dominate the market, while Asia Pacific is projected to emerge as the fastest-growing region due to expanding healthcare infrastructure and rising respiratory health concerns. Overall, the market presents strong opportunities for pharmaceutical companies focusing on innovative dosage forms and broader patient access.

Get Sample Link: https://www.precedenceresearch.com/sample/8293